This review investigates the similarities and differences between type 2 inflammatory phenotypes in COPD and asthma, with the aim of better addressing their diversities, gain deeper insights into their underlying cellular and molecular mechanisms, develop novel therapies in unmet areas, explore more effective treatment directions, reduce the disease burden, and enhance patient outcomes.